NASDAQ:SRNE - Sorrento Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.35 +0.05 (+0.94 %) (As of 08/17/2018 04:00 PM ET)Previous Close$5.35Today's Range$5.25 - $5.5552-Week Range$1.50 - $10.65Volume1.20 million shsAverage Volume2.71 million shsMarket Capitalization$630.35 millionP/E RatioN/ADividend YieldN/ABeta2.28 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California. Receive SRNE News and Ratings via Email Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical SymbolNASDAQ:SRNE CUSIPN/A Webwww.sorrentotherapeutics.com Phone858-203-4100 Debt Debt-to-Equity Ratio0.06 Current Ratio1.39 Quick Ratio1.39 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$151.85 million Price / Sales4.11 Cash Flow$0.2235 per share Price / Cash23.94 Book Value$2.50 per share Price / Book2.14 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$9.13 million Net Margins-15.77% Return on Equity-12.47% Return on Assets-5.70% Miscellaneous Employees162 Outstanding Shares116,730,000Market Cap$630.35 million Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions What is Sorrento Therapeutics' stock symbol? Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE." How were Sorrento Therapeutics' earnings last quarter? Sorrento Therapeutics Inc (NASDAQ:SRNE) posted its quarterly earnings data on Monday, November, 16th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter. The biopharmaceutical company earned $1.10 million during the quarter, compared to analyst estimates of $1.28 million. Sorrento Therapeutics had a negative net margin of 15.77% and a negative return on equity of 12.47%. View Sorrento Therapeutics' Earnings History. When is Sorrento Therapeutics' next earnings date? Sorrento Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 22nd 2018. View Earnings Estimates for Sorrento Therapeutics. What price target have analysts set for SRNE? 3 brokerages have issued 12-month target prices for Sorrento Therapeutics' stock. Their predictions range from $9.00 to $40.00. On average, they expect Sorrento Therapeutics' share price to reach $21.0833 in the next twelve months. This suggests a possible upside of 294.1% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics. What is the consensus analysts' recommendation for Sorrento Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics. Are investors shorting Sorrento Therapeutics? Sorrento Therapeutics saw a decrease in short interest during the month of July. As of July 13th, there was short interest totalling 18,119,806 shares, a decrease of 7.8% from the June 29th total of 19,659,939 shares. Based on an average trading volume of 1,813,051 shares, the days-to-cover ratio is currently 10.0 days. Currently, 20.7% of the company's stock are short sold. View Sorrento Therapeutics' Current Options Chain. Who are some of Sorrento Therapeutics' key competitors? Some companies that are related to Sorrento Therapeutics include Medpace (MEDP), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), VIRALYTICS Ltd/S (VRACY), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ) and Protalex (PRTX). Who are Sorrento Therapeutics' key executives? Sorrento Therapeutics' management team includes the folowing people: Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 54)Mr. George K. Ng, Exec. VP, Chief Admin. Officer & Chief Legal Officer (Age 44)Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 68)Mr. Jiong Shao CFA, Exec. VP & CFO (Age 50)Dr. Alexis Nahama, VP of Corp. Devel. Has Sorrento Therapeutics been receiving favorable news coverage? News headlines about SRNE stock have been trending somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sorrento Therapeutics earned a daily sentiment score of 0.11 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 48.94 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Sorrento Therapeutics. Who are Sorrento Therapeutics' major shareholders? Sorrento Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.18%), Bank of America Corp DE (0.38%), Renaissance Technologies LLC (0.30%), Vident Investment Advisory LLC (0.29%), Bank of New York Mellon Corp (0.27%) and Millennium Management LLC (0.23%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde, Pacific Medtech (Bvi) Ltd Asia and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics. Which major investors are selling Sorrento Therapeutics stock? SRNE stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, GSA Capital Partners LLP and Acadian Asset Management LLC. Company insiders that have sold Sorrento Therapeutics company stock in the last year include Abg Management Ltd and Pacific Medtech (Bvi) Ltd Asia. View Insider Buying and Selling for Sorrento Therapeutics. Which major investors are buying Sorrento Therapeutics stock? SRNE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vident Investment Advisory LLC, Bank of America Corp DE, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Integrated Wealth Concepts LLC, Swiss National Bank and State of Wisconsin Investment Board. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics. How do I buy shares of Sorrento Therapeutics? Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sorrento Therapeutics' stock price today? One share of SRNE stock can currently be purchased for approximately $5.35. How big of a company is Sorrento Therapeutics? Sorrento Therapeutics has a market capitalization of $630.35 million and generates $151.85 million in revenue each year. Sorrento Therapeutics employs 162 workers across the globe. How can I contact Sorrento Therapeutics? Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected] MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)Community Ranking: 3.5 out of 5 ( )Outperform Votes: 370 (Vote Outperform)Underperform Votes: 165 (Vote Underperform)Total Votes: 535MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/18/2018 by MarketBeat.com StaffFeatured Article: What does relative strength index mean?